A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis
For more information about the trial above please contact the study team:
Principal Investigator, Praneeth Baratam, at email@example.com.
Study Coordinator, Sarah Britton, at firstname.lastname@example.org, or please call +1 843-792-8856.
Trial opened at the following institutions: Medical University of South Carolina